Abstracts tagged "systemic lupus erythematosus (SLE) and tumor necrosis factor (TNF)"

Abstract Number: 757 • 2015 ACR/ARHP Annual Meeting
The Ratio Between TNF-a and P-Albumin – a Suggested Measure of Disease Activity in SLE
Susanna Eketjäll¹, Helena Idborg², Johanna Gustafsson³, Agneta Zickert², Marika Kvarnstrom⁴, Vilija Oke⁵, Susanne Pettersson⁴, Per Johan Jakobsson⁴, Iva Gunnarsson⁴ and Elisabet Svenungsson⁴, ¹Department of Clinical Neuroscience, Karolinska Institutet, Solna, AstraZeneca Translational Sciences Centre, Science for Life Laboratory, Personal Healthcare and Biomarkers, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of medicine, Unit of Rheumatology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: There is presently no consensus on how to best measure disease activity in systemic lupus erythematosus (SLE). Available validated measures, such as SLE Disease…
Abstract Number: 2202 • 2013 ACR/ARHP Annual Meeting
TNF-α Is Associated With Cognitive Impairment In Childhood-Onset Systemic Lupus Erythematosus
Mariana Postal¹, Nailu A. Sinicato¹, Aline T. Lapa¹, Karina Peliçari¹, Bruna Bellini¹, Paula T Fernandes², Roberto Marini³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculty of Physical Education, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Cognitive impairment is common in over 50% of SLE patients with active neurological and psychiatric disorders. Cytokine dysregulation and inﬂammation are mechanisms that may…
Abstract Number: 1416 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus
Mariana Postal¹, Aline T. Lapa¹, Nailu A. Sinicato¹, Karina Peliçari¹, Lilian Costallat² and Simone Appenzeller³, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, ³Medicine, Faculty of Medical Science, State University of Campinas Unicamp, São Paulo, Brazil
Background/Purpose: Elevated serum levels of tumor necrosis factor alpha (TNF-α) have been reported in patients with major depressive disorder and in patients with depression in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].